Mach7 wins five-year Temple Health imaging software contract

Temple Health contract adds recurring revenue

Mach7 Technologies Limited (ASX:M7T) has secured a five-year subscription agreement with Temple Health, a major Philadelphia academic health system, for its eUnity Viewer and Vendor Neutral Archive. The contract is expected to add A$0.5 million to Year 1 annual recurring revenue, assuming an AUD/USD exchange rate of 0.68.

The agreement became effective on 30 October 2026, but the revenue is not an immediate accounting win. Mach7 expects first productive use within six to 12 months, leaving the timing of the initial contribution dependent on implementation and go-live. The announcement does not disclose the contract's total value, payment terms or a precise go-live date.

Academic health system expands Mach7’s US footprint

Temple Health operates 990 licensed beds and has more than 1,700 physicians and 350 researchers across hospitals and specialist centres, including Temple University Hospital and Fox Chase Cancer Centre. Mach7 said its software will help clinicians access imaging information across the network, including in care involving multiple medical teams.

The customer win extends a subscription-led sales strategy that has already included multi-year subscription deals, while giving Mach7 another named customer in the academic health system and integrated delivery network market. The company’s eUnity platform and VNA are designed to manage, access and share diagnostic imaging data across complex healthcare environments.

Conversion to ARR is the next test

At A$0.5 million, the expected Year 1 ARR would represent a modest addition against Mach7’s reported A$23.5 million ARR run rate, although the comparison is not like-for-like because the figures relate to different reporting points and the new contract remains pre-go-live. Mach7 enters the deal after reporting a shift towards recurring revenue and a difficult FY26 in which revenue fell and losses widened.

The immediate question is execution rather than contract signing: whether Temple Health reaches first productive use within the indicated window and whether the expected ARR converts on the stated assumptions. Until then, the five-year term offers visibility, but not a fully realised revenue contribution.